J.C. Lopez

J.C. joined NEA in 2020 as a Principal on the healthcare team and focuses on biopharma investments. He joined the Centrexion board of directors in 2021 and is a board observer for 858 Therapeutics, Pionyr, Qpex, and Stablix.

Prior to NEA, J.C. led Global Search and Evaluation for Neuroscience, Ophthalmology, and Rare Diseases for Roche/Genentech. While at Roche/Genentech, J.C. sourced, led, and closed Genentech’s collaboration with Clover Therapeutics and was involved with Genentech’s collaborations with Convelo Therapeutics and Atalanta Therapeutics. As Global Search and Evaluation Lead, he was responsible for the sourcing, triaging, and initial diligence of opportunities in neuroscience, ophthalmology, and rare diseases. Prior to Roche/Genentech, J.C. held various roles as an intern at Militia Hill Ventures, where he focused on biotech company creation and as a Tech Transfer Fellow at the University of Pennsylvania’s Tech Transfer Office.

J.C. received a BS in Biological Sciences from Stanford University, an MD from The Perelman School of Medicine at The University of Pennsylvania, and an MBA from The Wharton School where he was a Joseph Wharton Fellow.